ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2450

Disease Progression in Anti-Centromere Positive Systemic Sclerosis Patients

Eva Hoekstra1, S. Ahmed2, David Ueckert3, Nina Ajmone Marsan3, Philippine Kiès3, M.K. Ninaber3, Marlies Heuvers3, Miranda Geelhoed3, Thomas Huizinga4 and Jeska de Vries-Bouwstra1, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Centre, Leiden, Netherlands, 3Leids Universitair Medisch Centrum, Leiden, Netherlands, 4Department of Rheumatology, Leiden University, Leiden, Netherlands

Meeting: ACR Convergence 2024

Keywords: prognostic factors, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Disease progression in systemic sclerosis (SSc) is characterized by severe and early progression in anti-topoisomerase (ATA) positive diffuse cutaneous patients and typically involves lung and skin. Disease progression in anti-centromere (ACA) patients is also frequently present, but more often consists of cardiac progression and happens typically not early but any time during the course of disease. We therefore hypothesize that disease progression in ACA-positive patients is driven by different factors than disease progression in ATA-positive patients. The aim of this study is to identify baseline characteristics that predict disease progression in ACA-positive SSc patients.

Methods: SSc patients fulfilling ACR/EULAR 2013 criteria were included form the Leiden CCISS cohort. Disease progression was defined as disease progression in one or more organ domains (including skin involvement, heart involvement, interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), renal involvement, myositis and gastro-intestinal involvement) or death. To identify possible baseline predictors for disease progression univariable and multivariable logistic regression with adjustment for age, sex and immunosuppressive use at baseline was performed.  

Results: In total 754 patients were included, with a median follow-up of 3.4 (1.1–7.1) years. Of 318 ACA-positive patients 160 (50%) suffered from disease progression during follow-up, compared to 62% in ACA-negative patients. In ACA-positive patients, cardiac progression occurred most frequently (31%), followed by disease subset progression (16%) and skin score progression (11%), whereas in ACA-negative patients disease progression most frequently involved cardiac progression (37%), ILD progression (20%) and skin score progression (17%) (Figure 1). In univariable analysis diffusing capacity for carbon monoxide (DLCO), 6 minute walking distance, oxygen saturation at rest and presence of contractures were significantly associated with disease progression in ACA-positive patients, while for the total group skin score, diffuse cutaneous subset, hemoglobin, and presence of radiographic ILD, pitting scars and friction rubs were predictive as well. In multivariable analysis DLCO percentage (OR 0.98 [0.97-0.99]), oxygen saturation at rest (OR 1.22 [1.04-1.43]) and contractures (OR 2.82 [1.71–4.68]) were significantly associated with disease progression.

Conclusion: Our study confirms that disease progression is substantial in ACA-positive patients. The baseline characteristics most predictive for progression in ACA-positive patients include DLCO percentage, oxygen saturation at rest and contractures, which were clearly different from predictors for the complete SSc group and should be taken into account in risk stratification in clinical practice. Our results underline the hypothesis that disease progression is driven by different factors in ACA-positive patients; further in-depth studies are warranted.

Supporting image 1

Figure 1. Disease progression stratified per organ domain in SSc patients.

Supporting image 2

Table 1. Baseline characteristics of anti-centromere positive and negative SSc patients.

Supporting image 3

Table 2. Association between baseline characteristics and disease progression in anti-centromere positive patients.


Disclosures: E. Hoekstra: None; S. Ahmed: Janssen, 1, 5; D. Ueckert: None; N. Ajmone Marsan: None; P. Kiès: None; M. Ninaber: None; M. Heuvers: None; M. Geelhoed: None; T. Huizinga: Abblynx, 2, 5, 6, Abbott, 2, 5, 6, Boehringer, 2, 5, 6, Bristol Myers Squibb, 2, 5, 6, Eli Lilly, 2, 5, 6, Galapagos, 2, 5, 6, Janssen, 2, 5, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 5, 6, Sanofi-Aventis, 2, 5, 6, UCB, 2, 5, 6; J. de Vries-Bouwstra: AbbVie/Abbott, 2, 6, Boehringer-Ingerlheim, 2, 6, Galapagos, 5, Janssen, 2, 5, 6, Roche, 5.

To cite this abstract in AMA style:

Hoekstra E, Ahmed S, Ueckert D, Ajmone Marsan N, Kiès P, Ninaber M, Heuvers M, Geelhoed M, Huizinga T, de Vries-Bouwstra J. Disease Progression in Anti-Centromere Positive Systemic Sclerosis Patients [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/disease-progression-in-anti-centromere-positive-systemic-sclerosis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-progression-in-anti-centromere-positive-systemic-sclerosis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology